Drug Profile

TYG 100

Alternative Names: APL-810; OQR 100; TYG - 100

Latest Information Update: 16 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator OncoQR
Developer Apollomics; OncoQR
Class Antineoplastics; Cancer vaccines; Immunotherapies
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer
New Molecular Entity No
Available For Licensing Yes - Gastric cancer; Oesophageal cancer; Pancreatic cancer

Highest Development Phases

Preclinical Gastrointestinal cancer
Discontinued Breast cancer; Gastric cancer; Pancreatic cancer

Most Recent Events

16 Mar 2023 Discontinued - Preclinical for Gastric cancer in Austria (IV)
16 Mar 2023 Discontinued for Pancreatic cancer in Austria (IV)
28 Feb 2023 No recent reports of development identified for preclinical development in Gastric-cancer in Austria (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com